Abstract:Aspergillus is widespread in the environment and causes a variety of tracheobronchial and pulmonary disorders, depending upon the alterations of immune status of hosts.[1] Among the spectrum of pulmonary aspergillosis (PA), allergic bronchopulmonary aspergillosis, and most chronic pulmonary aspergillosis are considered as non-invasive diseases, whereas invasive pulmonary aspergillosis (IPA) and subacute invasive pulmonary aspergillosis (SAIA) may cause tissue invasion. Blood vessel invasion, thrombo-mycotic occlusion, and hemorrhagic infarctions are characteristic pathological findings in angioinvasion pulmonary aspergillosis. In-situ pulmonary artery thrombosis (PAT) is a potentially life-threatening disorder, which is caused by inflammation and injury of pulmonary artery wall as well.[2] The therapy of PAT is similar with that of pulmonary thromboembolism (PTE), including thrombolysis and anti-coagulation, and hemoptysis is one of the most common complications. Anti-coagulation should be given or not, which may depend on different clinical situations. Here we present three cases with different clinical outcome, which could be helpful to set the diagnosis and therapy strategy of PA with in-situ PAT. Case 1. A 71-year-old man had a history of chronic obstructive pulmonary disease (COPD) and productive cough and dyspnea for 30 years. The symptoms exacerbated 15 days with edema of both lower extremities. Computed tomography pulmonary angiography (CTPA) [Figure 1A and 1B] showed cavity in right lobe and dorsal segment of lower lobe with fibrosis and pleural thickening. It also showed thrombosis in right main pulmonary artery, which was considered as in-situ PAT because of the close adjacent relationship between thrombosis and pulmonary lesion. He was treated with anti-coagulation. Then serum Galactomannan showed 1.11, sputum culture showed Aspergillus, which led to the diagnosis of IPA. With treatment of itraconazole, the patient improved then.Figure 1: Computed tomography images of the patients. (A) CTPA showed filling defect in right main pulmonary artery in case 1 (arrow). (B) CT showed cavity in right lobe and dorsal segment of lower lobe with fibrosis and pleural thickening in case 1. (C) Chest CT of case 2 showed maculas shadows in tip-posterior of left upper lobe. (D) CTPA showed filling defect in the arteries supplying the left upper lobe in case 2 (arrow). (E) Fourteen days later, the follow-up chest CT of case 2 showed lesion developed into consolidation rapidly. (F) CTPA of case 3 showed filling defect in right main pulmonary artery (arrow). (G) Cavity of bilateral lobes in case 3. (H) A follow-up CTPA (4 months later) of case 3 showed sever local pulmonary fibrosis. (I) Chest CT (1 month after CT of figure 1G) showed cavity, formation of new nodules, and progressive massive fibrosis in multiple lobes in case 3. CTPA: Computed tomography pulmonary angiography.Case 2. A 75-year-old man with COPD had fever, chest pain for 15 days. The CT scanning [Figure 1C] showing maculas shadows in tip-posterior of left upper lobe. He was diagnosed as IPA with microbiology of Aspergillus and was treated with voriconazole. A CTPA [Figure 1D] showed a filling defect in artery supplying the left upper lobe. He was diagnosed as in-situ PAT instead of PTE because of the close relationship of artery and lung parenchyma lesions. After 10-day anti-coagulation, the patient had hemoptysis, and a follow-up chest CT [Figure 1E] showed a rapid deterioration in lung. Anti-coagulation was stopped for persistent hemoptysis and anti-fungal therapy was continued. The patient improved after several weeks and continued oral voriconazole after discharging. Case 3. A 42-year-old woman, who got lung tuberculosis 12 years ago, with complaint of dyspnea and hemoptysis for 5 months, recurrence for 5 days. CTPA [Figure 1F and 1G] showed filling defect in right pulmonary artery, bronchiectasis, and cavities in multiple lobes. She was diagnosed as PTE and treated with warfarin, but stopped anti-coagulation because of hemoptysis. Four months later, CTPA [Figure 1H] showed serious local pulmonary fibrosis. Five days before admission, she had hemoptysis again. Chest CT [Figure 1I] showed cavity, formation of new nodules and progressive massive fibrosis, which clued the possibility of SAIA. Aspergillus immunoglobulin G antibody was positive and the diagnosis of SAIA was made. The pulmonary artery thrombotic lesion was diagnosed as in-situ PAT instead of PTE. Intra-venous itraconazole was used. At day 4 after admission, she suffered from fatal hemoptysis and died due to asphyxia. These three cases were all diagnosed as PA with in-situ PAT. In vivo experiment showed that Aspergillus hyphae stimulated tissue factor activity in vascular endothelial cell, revealing the potential mechanism of angioinvasion and thrombosis.[3] In addition, in patients with underlying pulmonary diseases, because of the pulmonary vascular remodeling, blood flow vortex is another risk factor of thrombosis. CTPA should be taken into to identify PAT if necessary. PAT is distinguished from PTE by pathophysiology and CTPA features. In PTE, thromboembolus migrates from venous of lower extremities to pulmonary artery, filling defects usually can be observed in bilateral pulmonary artery, whereas in-situ thrombus formation happens single often.[4] In patients with PAT, it displays mural thrombus with obtuse angles with vessel wall, but not common in patients with acute PTE. In these three cases, radiology demonstrated that embolism was single and located in main pulmonary artery adjunct to the lung lesions, distal arteries were unobstructed, the lesions of pulmonary parenchyma and artery fit together, consistent with in-situ PAT. It is important to notice the correlation between PA and PAT rather than simply PTE due to the therapy is more than anti-thromboembolism. There were only some sporadic cases of PA with PAT reported,[5–7] epidemiological data in population were not clear. IPA happened in both immunosuppressed and non-immunosuppressed patients. And thrombi in these cases were fungal thrombi proven by autopsy, among them, anti-fungal therapy was diverse, including triazole, Amphotericin B, and caspofungin. As for our cases, though there was no histopathology evidence, we supposed these thrombotic events were attributed to PAT according to clinical features. Anyway, anti-fungal therapy is essential, no matter for fungal thrombi or PA. For example, case 3 suffered SAIA for 5 months speculated by previous CTs, without standard anti-fungal therapy, Aspergillus spoiled vascular, and fatal hemoptysis as a severe complication resulted in poor prognosis. Yet patients in case 1 and 2 received anti-fungal therapy in time and recovered. It speculates that early diagnosis and anti-fungal therapy are critical for patients with angioinvasion. Voriconazole is approved for first-line therapy in invasive aspergillosis according to guidelines, combination of anti-fungal drugs may help in immunocompromised or critical-ill patients. The necessary of anti-coagulation therapy for PAT patients is unclear.[2] Anti-coagulation should be personalized in PA with PAT. According to the recommendations of the American College of Chest Physicians guideline of anti-thrombotic therapy for venous thromboembolism (VTE) disease,[8] bleeding estimation should be made in different anti-coagulation individuals. For example, the patient in case 2 was in high risk of bleeding with more than two bleeding risk factors, and got cessation of anti-coagulation after occurrence of hemoptysis. Anti-coagulation helped the improvement in case 1 while aggravated hemoptysis in case 3. The difference was decided by the treatment of underlying PA. In summary, differential diagnosis of PTE and PAT should be conducted when the lesions of pulmonary parenchymal and artery fit together. Anti-fungal treatment is essential, slowing vascular invasion and avoiding fatal hemoptysis. Anti-coagulation depends on the evaluation of the risk-benefit ratio. Funding This study was supported by grants from the National Natural Science Foundation of China (No. 81270117) and CAMS Innovation Fund for Medical Sciences (CIFMS) (No.2018-I2M-1-003). Conflicts of interest None.

Abstract:To the Editor: We here present a case of invasive pulmonary aspergillosis (IPA) with asthma and chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS). The patient recently took a high dose of systemic corticosteroids. Additionally, pneumothorax occurred, prompting right upper lobectomy, which contained the majority of the Aspergillus lesion. Full recovery occurred utilizing a combination of surgical resection and systemic antifungal therapy. This case supports a surgical approach to clear the infection when antifungal agents are inadequate. A 61-year-old male nonsmoker with poorly controlled asthma for 50 years developed fever, wheezing, expectoration on August 30, 2009. The total leukocyte count was 7.9 × 109/L, with neutrophils accounting for 80%. Chest radiology showed hyperinflation and mild emphysema, but no infiltrates. He was commenced on cefpiramide, inhaled budesonide and terbutaline, along with methylprednisolone (40 mg, intravenous [IV], tid) in other hospital. Afterward, the dose of methylprednisolone was increased to 80 mg, tid. Blood and sputum cultures both grew Gram-negative bacilli. With no evidence of remission, the patient was admitted to our hospital on October 1, 2009. Pulmonary function tests showed a forced expiratory volume in 1 s (FEV1)/forced vital capacity of 48.41%, FEV1 of 1.37 L (41.9% of predicted), maximum ventilatory volume of 50.1 L/min (49.4%), revealing persistent airflow limitation, even when he was in stable. The bronchial test revealed positive. Using GINA or GOLD guidelines, his diagnosis was consistent with ACOS. He had ACOS exacerbations triggered by upper respiratory tract infections once a year, and corticosteroids pulses were frequently administered. He has no other past history except ACOS. On admission, the temperature was 38.8°C, pulse 80 beats/min; blood pressure 135/80 mmHg; respiratory rate, 20 breaths/min. There was dullness to percussion of the upper right lung, diminished breath sounds and rales in both lungs. He had a decreased CD3+ T-cell (490/mm3, % predicted 50%), a CD4+ T-cell (118/mm3, % predicted 12%). Acid-fast bacilli smear test was negative. Blood and sputum cultures both grew methicillin-resistant coagulase-negative Staphylococcus. Blood beta-D-glucan was significantly elevated (2580 pg/ml), as well as galactomannan (2.66 pg/ml). The specific and total serum immunoglobulin E for Aspergillus was normal. On October 2009, chest computed tomography scans [Figure 1a and b] showed new right greater than left upper lobe infiltrates with the cavitary lesion formation.Figure 1: Axial images from chest computed tomography scan show the progression of the disease. (a and b): On October 19, 2009, shows bilateral lung infiltrations and cavitary lesions, prominently in right upper lung; (c and d): On November 16, 2009, shrinking cavitary lesions; (e and f): On December 21, 2009, unresolved pneumothorax; (g and h): On May 3, 2010, stable lesions in left upper lobe; (i and j): On August 2, lesions are mostly absorbed.The patient was treated empirically for asthma with IV methylprednisolone (40 mg, qd), inhaled budesonide, salbutamol, ipratropium bromide. Linezolid and imipenem were used for an anti-infection therapy. Meanwhile, the patient was commenced on IV itraconazole (ITR) (250 mg/d). On day 5 of the treatment, he defervesced. Neither acid-fast bacilli nor bacteria were detected. However, sputum culture still grew Aspergillus fumigatus. After 1-month of IV ITR, he was discharged with oral ITR (200 mg, bid). On November 15, 2009, the patient was readmitted with worse wheezing, as well as hemoptysis and lower extremities edema. Chest radiology showed shrinking cavitary lesions with bilateral lung [Figure 1c and d]. Sputum cultures persisted with Aspergillus 2+. Combination therapy with IV voriconazole (VRZ) (200 mg/d) and Caspofungin (CAS) (50 mg/d) was used. Two weeks after therapy, the patient suddenly developed increased shortness of breath. Chest X-ray revealed right pneumothorax. Persistent bronchopleural fistula with air leak persisted in the following 2 weeks [Figure 1e and f] despite chest tube suction. Though the patient was malnourished (albumin = 31.3 g/L), he underwent successful upper right lobectomy. Postoperative histology [Figure 2] demonstrated filamentous fungus growth in lung tissue. He improved markedly after surgery. The first postoperative sputum culture was negative. After the surgery, combination therapy was continued for another 2 months and then de-escalated to oral VRZ (400 mg/d).Figure 2: Histology of right upper lung shows filamentous fungus (H and E, original magnification ×200).After 6 months’ antifungal treatment, the patient reported again with cough, expectoration, and hemoptysis. Chest radiology revealed enlarged lesions in left upper lobe [Figure 1g and h]. IV VRZ (200 mg/d) and CAS (50 mg/d) were started on for 2 weeks. Symptoms significantly improved. Oral VRZ was continued for 3 months. Follow-up chest radiology showed improvement in the left upper lung [Figure 1i and j]. On August 12, 2010, oral VRZ was discontinued. The patient has had no recurrence of IPA but has periodically been treated for bacterial exacerbations of ACOS in the next 5 years. ACOS-related deficiencies in the airway epithelial barrier create a higher opportunity for Aspergillus colonization.[1] Meanwhile, systemic corticosteroids pulse also disposes the patient to IPA.[23] Treatment for IPA remains difficult, and prompt administration of antifungal agents should be considered after a clinical suspicion of IPA. VRZ is now indicated as a standard antifungal therapy. CAS is approved as salvage therapy after intolerance or failure of conventional antifungal therapy. For the combination therapy, no enough evidence supported as primary therapy, but it can act as a salvage antifungal therapy that supported by many studies reported a decrease in mortality in IPA.[4] In this case, the patient started with ITR as primary therapy since VRZ was not covered by the medical insurance in China. Due to the unsatisfied effect of 1-month single-antifungal therapy with ITR, we changed to the combination therapy with both VRZ and CAS. Conclusively, in this case, the unique mechanisms of combination therapy provided clinical benefits for the refractory IPA. For ACOS control, the GOLD guideline recommends that it is prudent to start treatment as for asthma until further investigation has been performed to confirm the COPD diagnosis. If COPD was assessed, treatment with bronchodilators or combination therapy was suggested. The patient has severe asthma. Treatment during stable periods is inhaled corticosteroid/long-acting beta-agonist. However, due to combined COPD, the long-acting muscarinic antagonist was added to control the symptoms. Surgery of an IPA focus is seldom used in ACOS patients due to the poor pulmonary function. However, in this case, the role of surgical lung resection cannot be ignored. While antifungal therapy is essential for IPA, often there is reduced lung tissue penetration, particularly notable with ITR, and residual lesions are often present.[5] Surgeries can potentially eradicate localized infection and simultaneously provide both a definitive diagnosis of IPA. In this case, negative fungus result was achieved in the first sputum culture after surgery, suggested that the surgery scavenged the majority of Aspergillus spp., thus reduced secondary dissemination. Besides, right upper lobectomy made intractable pneumothorax curable.

Pulmonary Aspergillosis with In-Situ Pulmonary Artery Thrombosis

A Case Report Of Pulmonary Thromboembolism Following Allergic Bronchopulmonary Aspergillosis

Utility of CT Assessment in Hematology Patients with Invasive Aspergillosis: a Post-Hoc Analysis of Phase 3 Data

P170 Life threatening hemoptysis in COVID-19 associated Pulmonary Aspergillosis (CAPA)

Integrated Therapy for Invasive Pulmonary Aspergillosis in a Patient with Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome

[Chronic Necrotizing Pulmonary Aspergillosis: Diagnosis and Treatment].

Interventional management of aspergillus-related pulmonary artery pseudoaneurysm and hemoptysis

[Management of hemoptysis in invasive pulmonary aspergillosis]

Clinical Findings in 19 Cases of Invasive Pulmonary Aspergillosis with Liver Cirrhosis

A Case of Pulmonary MALToma Camouflaged Within Invasive Pulmonary Aspergillosis

Is Video-Assisted Thoracic Surgery a Versatile Treatment for Both Simple and Complex Pulmonary Aspergilloma?

Pseudomembranous necrotizing tracheobronchial aspergillosis: an analysis of 16 cases.

Case Report: Apatinib Plus Selexipag As a Novel Therapy for Pulmonary Tumor Thrombotic Microangiopathy Accompanied by Pulmonary Hypertension Associated with Gastric Carcinoma.

Negative (1,3)-Β-d-glucan and Elevated White Blood Cells Combined Procalcitonin Masquerading As Severe Pneumonia Eventually Diagnosed As Invasive Pulmonary Aspergillosis Proven by Bronchoalveolar Lavage Fluid Culture in a Diabetes Patient: a Case Report and Literature Review

Clinical Features, Diagnostic Test Performance, and Prognosis in Different Subtypes of Chronic Pulmonary Aspergillosis

Clinical analysis of 30 patients with pulmonary aspergillosis

Intrapulmonary Teratoma Misdiagnosed As Aspergilloma

COVID-19 Associated Invasive Pulmonary Aspergillosis: Diagnostic and Therapeutic Challenges

Acute Invasive Pulmonary Aspergillosis: Clinical Presentation and Treatment

[Expert consensus on the diagnosis and treatment of pulmonary aspergillosis in patients with chronic obstructive pulmonary disease]

The First Case of Obstructing Bronchial Aspergillosis Caused by Aspergillus Sydowi